update on tirzepatide lawsuit FDA's decision creates uncertainty for patients—and leads to a Makers of Weight Loss Drugs
Description
Adding an oral dose with unpredictable absorption on top of residual injectable tirzepatide creates uncontrollable blood levels
Compounded versions are not FDA-approved, not generic equivalents, and are prescribed only when a licensed clinician determines they are appropriate for your history
Advise women of reproductive potential to inform their healthcare provider of a known or suspected pregnancy." Notice what the label does not say
Both medications are Schedule IV controlled substances due to their potential for dependence and misuse
Larger, prospective studies will be necessary to confirm these findings
